MP60-15 PRE-BIOPSY URINE EXOSOME 3-GENE SIGNATURE AND PATHOLOGY UPGRADING RISK IN RADICAL PROSTATECTOMY (RP)

You have accessJournal of UrologyProstate Cancer: Markers (MP60)1 Sep 2021MP60-15 PRE-BIOPSY URINE EXOSOME 3-GENE SIGNATURE AND PATHOLOGY UPGRADING RISK IN RADICAL PROSTATECTOMY (RP) Gordon Brown, Jason Alter, Michael Donovan, Sonia Kumar, Vasisht Tadigotla, Johan Skog, Mikkel Noerholm, Christian Fischer, and Grannum Sant BrownGordon Brown More articles by this author , AlterJason Alter DonovanMichael Donovan KumarSonia Kumar TadigotlaVasisht Tadigotla SkogJohan Skog NoerholmMikkel Noerholm FischerChristian Fischer SantGrannum View All Author Informationhttps://doi.org/10.1097/JU.0000000000002095.15AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION OBJECTIVE: Active surveillance (AS) is a management option for men with low-risk prostate cancer (GG1, PSA<10 ng/mL); however sampling error, genomic variability, multi-focality complicate AS shared decision-making. The ExoDx Prostate (EPI; Exosome Dx, US) pre-biopsy urine liquid biomarker test non-invasive validated risk assessment high-grade (HGPCa). Herein, we explore the potential EPI predict surgical pathology upgrading on RP) as an aid in categorizing patients who may be less suitable AS. METHODS: Men no history PCa, >50yrs, PSA 2-10 ng/mL, were scheduled diagnostic biopsy (Bx). First-catch, pre-Bx was collected (sites US, Europe) tests performed. We focus Gleason Grade Group 1 (GG1) underwent RP instead scores GG1-group compared multiparametric linear regression model using clinical covariates PSA, age, ethnicity family correlation pathologic RP. RESULTS: Samples from N=1563 (2014 2020). 295 subsequently proceeded further subset (N=106, 36%) had GG1 Bx. Between Bx-GG1 (N=106) Bx>GG1 (N=189) groups, found significant differences age (60 [57-65] vs 64 [59 - 68] years; p=0.61), value (median 5.32 [4.3 6.47] 5.48 7.0] ng/mL; p=0.66), African ancestry (2.8% 7.4%; p=0.89) or PCa (32% 25%; p=0.33). In group, 45% (48) confirmed 55% (58) upgraded – 41% (43) GG2, 11% (12) GG3, 1% (1) GG4, 2% (2) GG5. showed between groups (p>0.1). remained those GG2 difference (p=0.45), whereas significantly higher (p<0.01) ≥GG3 CONCLUSIONS: current study provides initial evidence that test, HGPCa stratification, assessing cancer. assay might more appropriately assess tumor heterogeneity thus role decision-making newly diagnosed Source Funding: Study funded Diagnostics, Waltham, MA, USA © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1047-e1048 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand Loading ...